Helocyte, Inc. — Form D/A
Helocyte, Inc. of NEW YORK, NY, a company, filed a Form D amendment with the SEC on 2016-11-04. The offering totals $5.0M, of which $4.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2016-11-04
- Form: D/A
- Accession: 0001679808-16-000003
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $5.0M
- Amount sold: $4.0M
- Remaining: $1.0M
- Investors: 61
- Date of first sale: 2016-10-31
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-267116
Issuer
- Name: Helocyte, Inc.
- CIK: 0001679808
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 2 GANSEVOORT STREET, NEW YORK, NY, 10014
- Phone: 212-554-4520
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Kenneth W Cappell | Director | New Yor, NY |
| Lindsay A Rosenwald | Director | New York, NY |
| Frank Taffy | Director | Hoboken, NJ |
| Michael S Weiss | Director | New York, NY |
| DAVID J HORIN | Executive Officer | NEW YORK, NY |
| Elizabeth Clark Moore | Executive Officer | New York, NY |
| Frank Taffy | Executive Officer | Hoboken, NJ |
Other filings by this issuer (2)
More